BRPI1011971A2 - uso de alopurinol para o tratamento de reações na pele das mãos e dos pés. - Google Patents

uso de alopurinol para o tratamento de reações na pele das mãos e dos pés.

Info

Publication number
BRPI1011971A2
BRPI1011971A2 BRPI1011971A BRPI1011971A BRPI1011971A2 BR PI1011971 A2 BRPI1011971 A2 BR PI1011971A2 BR PI1011971 A BRPI1011971 A BR PI1011971A BR PI1011971 A BRPI1011971 A BR PI1011971A BR PI1011971 A2 BRPI1011971 A2 BR PI1011971A2
Authority
BR
Brazil
Prior art keywords
allopurinol
feet
hands
treatment
skin reactions
Prior art date
Application number
BRPI1011971A
Other languages
English (en)
Portuguese (pt)
Inventor
Yolanda Rodemer
Original Assignee
Advancell Advanced In Vitro Cell Technologies S A
Nobera Pharma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancell Advanced In Vitro Cell Technologies S A, Nobera Pharma Sl filed Critical Advancell Advanced In Vitro Cell Technologies S A
Publication of BRPI1011971A2 publication Critical patent/BRPI1011971A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1011971A 2009-04-29 2010-04-29 uso de alopurinol para o tratamento de reações na pele das mãos e dos pés. BRPI1011971A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (1)

Publication Number Publication Date
BRPI1011971A2 true BRPI1011971A2 (pt) 2016-04-26

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011971A BRPI1011971A2 (pt) 2009-04-29 2010-04-29 uso de alopurinol para o tratamento de reações na pele das mãos e dos pés.

Country Status (22)

Country Link
US (2) US8623878B2 (enExample)
EP (2) EP2246057A1 (enExample)
JP (1) JP6007101B2 (enExample)
KR (1) KR20120049848A (enExample)
CN (1) CN102421436B (enExample)
AR (1) AR076505A1 (enExample)
AU (2) AU2010243594A1 (enExample)
BR (1) BRPI1011971A2 (enExample)
CA (1) CA2759085C (enExample)
DK (1) DK2424538T3 (enExample)
ES (1) ES2434366T3 (enExample)
HR (1) HRP20131070T1 (enExample)
IL (1) IL215831A (enExample)
ME (1) ME01567B (enExample)
MX (1) MX2011011529A (enExample)
NZ (1) NZ595901A (enExample)
PL (1) PL2424538T3 (enExample)
PT (1) PT2424538E (enExample)
RS (1) RS53005B (enExample)
RU (1) RU2543325C2 (enExample)
SI (1) SI2424538T1 (enExample)
WO (1) WO2010125143A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010306671B2 (en) 2009-10-16 2015-12-17 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
CA3085013A1 (en) 2017-12-13 2019-06-20 Onquality Pharmaceuticals China Ltd. A method for preventing or treating egfr-inhibition associated diseases
CN113975264A (zh) * 2018-04-16 2022-01-28 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents
US20250114362A1 (en) 2022-01-05 2025-04-10 Asymmetric Therapeutics, Llc Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
KR20250056445A (ko) * 2023-10-19 2025-04-28 (주) 수파드엘릭사 수족증후군 또는 수족피부반응의 예방 또는 치료용 약학 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3772193D1 (de) * 1987-02-13 1991-09-19 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JP4822652B2 (ja) * 2000-11-22 2011-11-24 エンド ファーマシューティカルズ インコーポレイテッド 粘膜炎の治療
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
US20030157191A1 (en) * 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
WO2004110380A2 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050148907A1 (en) * 2003-12-24 2005-07-07 Gregory Skover Treatment of skin using a benefit agent and an apparatus
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
ES2312012T3 (es) 2004-09-17 2009-02-16 Biomas Ltd. Nuevos compuestos de telurio y su uso como inmunomodulares.
HRP20100210T1 (hr) 2006-06-01 2010-05-31 Nobera Pharma Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala

Also Published As

Publication number Publication date
CN102421436B (zh) 2014-05-07
US20100280051A1 (en) 2010-11-04
RS53005B (sr) 2014-04-30
US20140080845A1 (en) 2014-03-20
PL2424538T3 (pl) 2014-05-30
DK2424538T3 (da) 2013-11-04
KR20120049848A (ko) 2012-05-17
IL215831A0 (en) 2012-01-31
CA2759085C (en) 2016-08-16
EP2246057A1 (en) 2010-11-03
RU2543325C2 (ru) 2015-02-27
ES2434366T3 (es) 2013-12-16
PT2424538E (pt) 2013-11-07
RU2011148355A (ru) 2013-06-10
NZ595901A (en) 2013-11-29
ME01567B (me) 2014-04-20
EP2424538B1 (en) 2013-08-14
US8623878B2 (en) 2014-01-07
WO2010125143A1 (en) 2010-11-04
CA2759085A1 (en) 2010-11-04
AU2016228193A1 (en) 2016-11-03
JP6007101B2 (ja) 2016-10-12
HK1168042A1 (en) 2012-12-21
MX2011011529A (es) 2012-02-08
SI2424538T1 (sl) 2013-12-31
IL215831A (en) 2016-02-29
CN102421436A (zh) 2012-04-18
HRP20131070T1 (hr) 2013-12-20
EP2424538A1 (en) 2012-03-07
AR076505A1 (es) 2011-06-15
AU2010243594A1 (en) 2011-11-10
JP2012525358A (ja) 2012-10-22

Similar Documents

Publication Publication Date Title
BRPI1016234A2 (pt) dispositivo aplicador para uso médico e/ou cosmético.
PT2306970E (pt) Uso cosmético de lactobacillus paracasei para o tratamento de pele oleosa
BRPI0912290A2 (pt) detergentes para pele e mãos.
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
PT2619576T (pt) Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
BR112012029746A2 (pt) composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
BR112012000417A2 (pt) aparelho para uso em tratamento terapêutico e/ou cosmético
BRPI0909251A2 (pt) Composição para o cuidado da pele
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0908428A2 (pt) uso de ranozalina para tratar a dor.
PT2796457T (pt) Genz 112638 para o tratamento de doença de gaucher ou de fabry em terapia de associação
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
BRPI1016199A2 (pt) cobertura de ferimento e kit de tratamento de ferimentos.
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
EP2229960A4 (en) MATERIAL FOR WOUND HEALING / SKIN RECONSTRUCTION
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
BR112013001709A2 (pt) apareçhp para a avaliação do estado da pele ou do cabelo
BR112013023743A2 (pt) anticorpo de fator de tecidos humanos e usos do mesmo
BRPI0812264A2 (pt) Vesícula, e, preparação externa para pele
SMT201700492T1 (it) Metodi analitici e array per l'uso nell'identificazione di agenti di induzione di sensibilizzazione nella cute umana
BRPI0920419A2 (pt) pinça para o osso e a pele.
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]